Welcome to our dedicated page for Angiodynamics SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to skip straight to the vascular-device details that matter? Investors often dive into AngioDynamics SEC filings looking for FDA clearance updates, segment revenue from thrombectomy systems, or trends in disposable kit sales. Yet each document can span hundreds of pages. Our platform delivers AngioDynamics SEC filings explained simply, guiding you to the precise tables and risk factors you need.
Start with the AngioDynamics annual report 10-K simplified section for a clear view of R&D spending and product pipeline milestones. Track performance quarter-to-quarter through every AngioDynamics quarterly earnings report 10-Q filing, automatically tagged with AI-generated margin and cash-flow summaries. Need real-time alerts? We stream AngioDynamics Form 4 insider transactions real-time so you can monitor AngioDynamics executive stock transactions Form 4 alongside key officers’ trading patterns.
Our AI also answers natural questions, from “What changed in the latest AngioDynamics 8-K material events explained?” to deeper AngioDynamics earnings report filing analysis. Use the proxy tab to explore AngioDynamics proxy statement executive compensation without scrolling through appendices. Features include:
- AI-powered summaries that flag revenue drivers and litigation updates
- Real-time EDGAR feeds for every filing type, from S-8 to 424B
- Side-by-side redlines that make understanding AngioDynamics SEC documents with AI effortless
- Instant download of all AngioDynamics insider trading Form 4 transactions in CSV format
No more fishing through dense legal language. Whether you’re verifying catheter sales growth or checking leadership’s stock moves, our AI surfaces the data so you can make informed decisions faster.
Armistice Capital and Steven Boyd report a passive 3.76% stake in AngioDynamics (ANGO). The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as managing member, share voting and dispositive power over 1,527,815 shares. The stake is based on 40,633,885 shares outstanding as of May 31, 2025, per the issuer's 10-K. The Reporting Persons state the holdings were acquired in the ordinary course of business and not to influence control of the company. The Master Fund is the direct holder while Armistice exercises voting and investment authority under an investment management agreement.
Divisadero Street Capital and related entities report ownership of material stakes in AngioDynamics common stock. The filing shows Divisadero Street Capital Management, LP and affiliated entities report beneficial ownership of 3,395,430 shares, representing 8.4% of the class, while Divisadero Street Partners, L.P. and its GP report 3,054,469 shares (approximately 7.5%). The reported positions are held with shared voting and dispositive power only; no reporting person asserts sole voting or sole dispositive power.
The filing states that all reported securities are directly owned by advisory clients of Divisadero Street Capital Management, LP and that each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest. The filing includes a joint filing agreement and a control-person identification exhibit.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
